The Integrated Forecasting and Analysis Tool   Login Now

Basilea Pharmaceutica

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Basilea Pharmaceutica are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Basilea Pharmaceutica, or on any other Company covered by EvaluatePharma® Contact Us today.

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) Basilea Pharmaceutica 1 Alitretinoin Dermatology Other dermatologicals Retinoid Filed   2 Isavuconazole Systemic Anti-infectives Anti-fungals Anti-fungal Phase III   - Ceftobiprole Systemic Anti-infectives Anti-bacterials Cephalosporin Filed

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Basilea Pharmaceutica   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 1,492 1,492        PE Ratio (diluted) - Normalised (x) (29.2) (17.7)        Valuing the Enterprise        Enterprise Value 1,073 1,073        Free Cash Flow (Pre-Dividends) 27 (59)        FCF Yield (%) 2.5% (5.5%)    Forecast Financials   Income Statement      Total Revenues 25 6      S,G & A (7) (10)      R&D (58) (66)      Other Income/ Expense - Net 0 0      EBIT - Normalised (41) (70)      Net Interest & Financial Items 1 2      Pre-tax Profits - Normalised (40) (68)      Income Before Taxes (40) (68)      Tax 0 0      Tax Rate (%) 0.0% 0.0%      Net Income - Reported (40) (68)      Net Income - Normalised (40) (68)     Per Share Data      EPS - Diluted (5.39) (8.87)      EPS - Basic (5.39) (8.87)      EPS - Normalised (diluted) (5.39) (8.87)      EPS - Normalised (basic) (5.39) (8.87)      Avg. Shares Outstanding - Diluted 7.4 7.7      Avg. Shares Outstanding - Basic 7.4 7.7      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

Ceftobiprole Shows High Cure Rates in Patients Hospitalized With Community-Acquired Pneumonia   (Basilea Pharmaceutica)   20-May-2008 Canadian Regulatory Authority Has Accepted New Drug Submission for Alitretinoin for Review   (Basilea Pharmaceutica)   05-May-2008 Arpida's troubles could be infectious   (Arpida)   18-Apr-2008 Basilea Opens New Phase III Study in Special Patient Populations for Its Broad-spectrum Antifungal Isavuconazole   (Basilea Pharmaceutica)   15-Apr-2008 FDA issues Approvable Letter for Ceftobiprole, a New Anti-MRSA Broad-Spectrum Antibiotic   (Basilea Pharmaceutica)   18-Mar-2008 Basilea plunges on ceftobiprole delay, but concerns go deeper   (Basilea Pharmaceutica)   18-Mar-2008 FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections   (Johnson & Johnson)   18-Mar-2008 FDA Published Today That it Will Not Hold an Advisory Committee Meeting on Ceftobiprole in the Treatment of Complicated Skin and Skin Structure Infections   (Basilea Pharmaceutica)   13-Feb-2008 Basilea looks mistreated by stock market   (Basilea Pharmaceutica)   11-Jan-2008 Basilea Announces Review of Ceftobiprole NDA at FDA Anti-Infective Drugs Advisory Committee Meeting   (Basilea Pharmaceutica)   10-Jan-2008 Basilea Announces Filing of New Drug Submission in Canada for Alitretinoin   (Basilea Pharmaceutica)   21-Dec-2007 Swiss Regulatory Authority Accepts for Review the Marketing Authorization Application for Alitretinoin   (Basilea Pharmaceutica)   15-Oct-2007 Marketing Authorization Application for Alitretinoin Accepted by European Health Authorities   (Basilea Pharmaceutica)   11-Oct-2007 Basilea Announces Positive Top-line Data from Phase III Study of Ceftobiprole in Hospital-Acquired Pneumonia   (Basilea Pharmaceutica)   09-Oct-2007 New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections   (Johnson & Johnson)   08-Oct-2007 Swiss Regulatory Authority Accepts Marketing Authorization Application for Ceftobiprole for Assessment   (Basilea Pharmaceutica)   08-Oct-2007 Basilea Announces Submission of Marketing Authorization Application for Alitretinoin to Swiss Regulatory Authority   (Basilea Pharmaceutica)   28-Sep-2007 New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA   (Johnson & Johnson)   18-Sep-2007 Results of Ceftobiprole Phase III Program for the Treatment of Complicated Skin Infections Presented Today at ICAAC   (Basilea Pharmaceutica)   18-Sep-2007 Basilea Presents Research Data at ICAAC on Novel Antibiotic Addressing the Emerging Threat from Multi-Resistant Gram-Negative Bacteria   (Basilea Pharmaceutica)   17-Sep-2007 Canadian Regulatory Authority has Accepted for Review New Drug Submission for Ceftobiprole   (Basilea Pharmaceutica)   14-Sep-2007 Basilea Announces Positive Top-line Data from Phase III Study of Ceftobiprole in Community-Acquired Pneumonia Requiring Hospitalization   (Basilea Pharmaceutica)   14-Sep-2007 New Data to be Presented on Key Basilea Compounds at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)   (Basilea Pharmaceutica)   13-Sep-2007 Basilea Announces the Submissions of Marketing Authorization Applications in the EU for Alitretinoin, an Investigational Drug for the Treatment of Severe Refractory Chronic Hand Eczema   (Basilea Pharmaceutica)   11-Sep-2007 Basilea Announces Submission of Marketing Authorization Application for Ceftobiprole by Janssen-Cilag AG to Swiss Regulatory Authority   (Basilea Pharmaceutica)   23-Aug-2007 U.S. FDA and European EMEA Accept Registration Applications for Ceftobiprole, a Novel Anti-MRSA Broad-Spectrum Cephalosporin   (Basilea Pharmaceutica)   18-Jul-2007 Basilea Announces Filing of New Drug Submission in Canada for Ceftobiprole   (Basilea Pharmaceutica)   17-Jul-2007 Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole, a Novel Anti-MRSA Broad-Spectrum Cephalosporin   (Basilea Pharmaceutica)   18-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Basilea Pharmaceutica Alitretinoin alitretinoin   Anti-bacterial Research Program (Basilea) -   BAL19403 -   BAL2299 cyclohexanediol   BAL27862 -   BAL30376 -   BAL8349 -   Ceftobiprole ceftobiprole   Isavuconazole isavuconazole   Ketolides -   Leader Peptidase -

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 13:57:08 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd